When utilized effectively, genetic testing for cancer risk-increasing mutations, (such as pathogenic mutations in the BRCA1 and BRCA2 genes) can identify high-risk individuals prior to cancer development, allowing for tailored interventions aimed at early cancer detection and prevention. Here, BRCA2 is linked to cancer.